Test/Panel Name	Test No.
VistaSeq® Hereditary Cancer Panel	481220
VistaSeq® without BRCA1 and BRCA2 genes	481240
VistaSeq® Breast Cancer Panel	481319
VistaSeq® High/Moderate Risk Breast Cancer Panel	481452
VistaSeq® GYN Cancer Panel	481330
VistaSeq® Breast and GYN Cancer Panel	481341
VistaSeq® MLH1 Comprehensive Analysis	483496
VistaSeq® MSH2 Comprehensive Analysis	483508
VistaSeq® MSH6 Comprehensive Analysis	483520
VistaSeq® PMS2 Comprehensive Analysis	483532
VistaSeq® Lynch Syndrome Panel	483543
Mutation-specific Sequencing	640/641 451382



References

Specimen requirements: 10 mL whole blood lavender-top (EDTA) tube OR

2 mL saliva Oragene®•Dx saliva collection kit

A continuity of care, pioneering science, professional service

We provide the scientific expertise you need, and the customer experience patients want.

Rapid results

Samples have a typical turnaround time of three to four weeks after a test arrives at our lab.

Extensive managed care contracts

Help patients maximize their benefits.

Convenient blood draws


We have a nationwide network of patient service centers, allowing for convenient access to sample collection. Visit **Labcorp.com** to find your nearest location.

Genetics expertise

Nationwide access to genetic counseling services for patients, providing comprehensive or results counseling at their convenience. Laboratory focused genetic counselors offer healthcare providers support in test selection and ordering.

Women's health and wellness

Labcorp provides access to a complete women's health offering featuring a full range of testing and services that support the continuity of care for your patients through a single laboratory.



https://www.cancer.gov/about-cancer/causes-prevention/genetics. Accessed October 11, 2021.

2. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. NCCN Guidelines Version 1.2022. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed August 16, 2021.







GENETICS & WOMEN'S HEALTH

VistaSeq[®] Hereditary Cancer Panels

An assessment of genetic mutations associated with hereditary cancer syndromes



Expand your patients' understanding of their hereditary cancer risk



Hereditary cancer syndromes

The mapping of the human genome has provided medical professionals with the ability to refine a patient's cancer risk through an analysis of inherited (germline) mutations. Approximately five to ten percent of cancers are thought to be caused by mutations in genes that are associated with hereditary cancer syndromes.¹

- Genetic mutations have been associated with more than 50 hereditary cancer syndromes¹
- Patients with genetic mutations are at a higher risk of developing certain types of cancer than the general population
- Genetic tests can help confirm whether a patient's condition is the result of an inherited cancer syndrome
- Genetic tests can also help identify family members at risk for developing cancers associated with a hereditary cancer syndrome

VistaSeq hereditary cancer panels - indications for testing²

- When a patient's personal or family medical history suggests a hereditary cancer syndrome
- When a patient's personal or family history could be explained by more than one hereditary cancer syndrome, a multi-gene panel test provides clinicians with an assessment of multiple cancer susceptibility genes in a cost-effective and efficient manner
- When a patient has tested negative or indeterminate for mutations in a single cancer susceptibility gene but has a personal and/or family history that suggests a hereditary predisposition for cancer

Broadening Your Patients' Options

VistaSeq Hereditary Cancer Panels are designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. They are specifically designed to detect inherited mutations and are not appropriate for the detection of mutations in acquired cancers.

Identifying your patients' risk

VistaSeq hereditary cancer panels are multi-gene tests that detect inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers.

Gene	VistaSeq 27 genes	VistaSeq without <i>BRCA</i> 25 genes	VistaSeq Breast 19 genes	VistaSeq High/Mod Risk Breast 9 genes	VistaSeq GYN 11 genes	VistaSeq Breast and GYN 25 genes	VistaSeq Lynch Syndrome 5 genes
APC	Х	Х					
ATM	X	X	X	X		Χ	
BARD1	X		X			Χ	
BMPR1A	X	X					
BRCA1	X		X	X	X	X	
BRCA2	X		X	X	X	X	
BRIP1	X	X	X			X	
CDH1	X	X	X	X		Χ	
CDK4	X	X					
CDKN2A	X	X					
CHEK2	X	X	X	X	X	X	
EPCAM	X	X			X	X	X
FAM175A	X	X	X			Х	
FANCCC						X	
MLH1	X	X			X	X	Х
MRE11A			X			Х	
MSH2	X	X			X	Х	Х
MSH6	X	X			Х	Х	Х
MUTYH	X	X	X		Х	Х	
NBN	X	X	X			Х	
NF1			X			Х	
PALB2	X	X	X	X		Х	
PMS2	X	X			X	Х	Х
PRKAR1A	X	X					
PTEN	X	X	X	X	Х	Х	
RAD50			X			Х	
RAD51C	X	X	X			Х	
RAD51D	X	X	X			Х	
SMAD4	X	X					
STK11	X	X	X	X		X	
TP53	X	X	X	X	X	X	

To see a complete listing of our VistaSeq hereditary cancer panel offerings, visit www.integratedgenetics.com or www.labcorp.com.